Associate Director, Commercial Applications (Bridgewater)

The Associate Director, Commercial Applications is a high-impact individual contributor responsible for providing strategic expertise and hands-on oversight for the implementation, integration, and maintenance of Commercial Applications across the US Solid Tumor and Hematology franchises, as well as future therapeutic indications.

This role leads all aspects of system process integration, vendor management, and technical deployment support. Acting as a crucial bridge between commercial strategy and technical execution, the successful candidate ensures that technology platforms optimally support field forces, marketing teams, and cross-functional partners. This role will report to the AVP, Commercial Excellence.

Responsibilities:

Strategic Technology Management & Implementation

• Solution Architecture: Assess evolving business needs to proactively drive analytics and technology solutions on behalf of the Commercial organization, ensuring absolute alignment with both internal and external partners.
• System Transitions: Provide deep subject matter expertise to configure Veeva Vault applications (CRM, PromoMats, MedComms, Link); successfully manage the platform transition from Salesforce.com to Veeva Vault and take full ownership from transition teams or third-party consultants.
• Data & System Integration: Develop and manage robust data integration workflows connecting Veeva platforms with critical data architecture, including Commercial Data Warehouses (Azure, Snowflake, Databricks), Master Data Management (Reltio), Concur, OneKey, Speaker Programs, and external data assets.
• Omni-Channel Execution: Lead the integration of digital automation initiatives, ensuring Omni-Channel Marketing efforts are seamlessly aligned and embedded within CRM systems.

Operations & Platform Administration

• Core Administration: Act as the primary administrator for various Veeva applications and modules, managing routine and customized enhancements.
• Periodic Commercial Processes: Own and execute periodic operational processes, including territory alignments, targeting, call plans, salesforce sizing modifications, field surveys, Veeva Suggestions, and custom report building.
• Quality Assurance & Governance: Oversee all Quality Assurance (QA) testing associated with application updates and ensure all deployed solutions comply fully with industry regulations and internal policies.
• Agile Lifecycle Delivery: Apply a disciplined approach to the agile development lifecycle, executing seamlessly across development, testing, deployment, and performance monitoring phases.

Cross-Functional Collaboration & Training

• Stakeholder Alignment: Collaborate extensively with cross-functional teams—including Sales, Marketing, Medical Affairs, PRC Administration, and Market Access (Oncology Access Directors)—to deliver comprehensive, unified technology solutions.
• Field Empowerment: Design and deliver comprehensive Veeva platform training and support to empower field users and drive optimal system adoption.
• Vendor & Partner Management: Act as a motivated self-starter and project lead, directing third-party consultants and vendors throughout the implementation and maintenance phases.

Qualifications:

• Education: BA/BS degree in a relevant field is required; a Master’s degree is considered a strong plus.
• Industry Experience: 8–10 years of progressive experience within the pharmaceutical or biotech industry, specifically within a Commercial role (e.g., Sales, Marketing, Commercial Operations, or Commercial IT)
• Veeva Expertise: Demonstrated hands-on experience across the Veeva ecosystem, including Veeva CRM, Veeva Vault (PromoMats, MedComms), Veeva Network, Approved Emails, and CLM.

Core Competencies & Skills:

• Business Process Knowledge: Deep familiarity with Life Sciences Commercial Business Processes, including Customer Engagement, Territory Alignment, Targeting/Segmentation, Incentive Compensation, and Marketing Operations.
• Technical Acumen: Functional understanding of modern data ecosystems (Snowflake, Databricks, Azure) and MDM platforms (Reltio).
• Communication & Leadership: Exceptional communication and interpersonal skills, with a proven ability to lead, influence, and guide internal customers and cross-functional stakeholders through complex technology rollouts.

Work Location: Minimum of three days in Bridgewater, NJ (Hybrid role)

Base Salary Range of $152,000-$202,000. Menarini Stemline offers generous compensation and benefits packages, including Short Term Incentive and Long Term Incentive Programs, Fidelity 401(k) (with 6% company match), Anthem Premier PPO and HDHP insurance plans, Company paid Basic Life & AD&D insurance and pre-tax FSA/HSA programs.

Please note: this position is classified as a corporate office position. Per the New York employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Menarini Stemline is committed to creating an inclusive environment for all employees. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, or status as a protected veteran.

Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

The Menarini Group is present in 70 countries and our products are sold in 140 locations around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of around 18,000 employees, every year more than 500 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients distributed across 6 continents.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of hematological and solid tumors. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved

treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy. Tagraxofusp is also being evaluated as both a single agent and in combination, in other CD123+ indications, including acute myeloid leukaemia (AML), chronic myelomonocytic leukaemia (CMML), and myelofibrosis (MF).

Additionally, Menarini received exclusive rights to commercialize Selinexor for the treatment of oncology indications in the European Union and other European countries (including the United Kingdom), Latin America and other key countries. Menarini has signed an exclusive licensing agreement with Karyopharm Therapeutics for the rights to commercialise an innovative therapeutic option in Europe, Latin America, Turkey, Russia, and CIS countries. Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear export compound for the treatment of hematologic cancers and solid tumours. It is already marketed in the US for multiple myeloma and is under development for solid tumour indications. Selinexor is registered in the EU for both early and late lines.

Menarini entered into a global license agreement with Radius Health to complete the development of Elacestrant, an oral SERD in late-stage Phase 3 development for hormone receptor-positive advanced breast cancer. Following a successful phase 3 study, Menarini Stemline received FDA approval in January 2023 under priority review and successfully oversaw a strong launch in February to the US market with the EMA review process concluded positively in September 2023.

It is an exciting time in the company’s development and an excellent opportunity for individuals joining us to contribute to building and shaping Menarini Stemline’s Oncology business.